On Sunday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced multiple program updates, including: In December, the FDA approved Vertex's Alyftrek (vanzacaftor / tezacaftor ...
Hosted on MSN25d
Jim Cramer on Vertex Pharmaceuticals Incporated (VRTX): ‘This Is Hardly Down For The Year. I Think It Can Still Go Lower’In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other stocks. In his second appearance on Squawk on the Street after the ...
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...
Avi Kapoor Vertex Grapples With Bearish Chart As Death Cross Emerges Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months.
Jefferies analyst Michael Yee has maintained their bullish stance on VRTX stock, giving a Buy rating today. Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter ...
Citi analyst Geoff Meacham maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of $575.00. The company’s shares closed last Friday at ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback